• Issue

    Cancer: Volume 131, Issue 7

    1 April 2025
Previous Issue
Export Citation(s)

ISSUE INFORMATION

Free Access

Issue Information

  • First Published: 19 March 2025

ORIGINAL ARTICLE

Disease Site

Gastrointestinal Disease

Open Access

A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G)

Nozomu Machida MD, PhD,  Takehiro Okumura MD,  Narikazu Boku MD, PhD,  Junji Kishimoto MA,  Tomohiro Nishina MD, PhD,  Koichi Suyama MD, PhD,  Yasuhisa Ohde MD, PhD,  Katsunori Shinozaki MD, PhD,  Hideo Baba MD, PhD,  Shinya Tokunaga MD,  Hisato Kawakami MD, PhD,  Takashi Tsuda MD, PhD,  Masahito Kotaka MD, PhD,  Hiroyuki Okuda MD, PhD,  Hisateru Yasui MD,  Kentaro Yamazaki MD, PhD,  Shuichi Hironaka MD, PhD,  Kei Muro MD, PhD,  Ichinosuke Hyodo MD, PhD, 
  • First Published: 25 March 2025

This prospective phase 2 study of adjuvant chemotherapy with 12 cycles of modified 5-fluorouracil/leucovorin and oxaliplatin after metastasectomy of lung metastasis from colorectal cancer showed favorable outcomes: a 5-year overall survival rate of 85.2% (95% confidence interval [CI], 71.4%–92.6%), a 5-year disease-free survival rate of 60.2% (95% CI, 44.9%–72.4%), and a feasible completion rate of 78.8%.

Discipline

Psychosocial Oncology

Open Access

Utilization and perceptions of chaplaincy among hospitalized adults of Dharmic religions with cancer

Rushil V. Patel MD,  Jill M. Bowden MDiv, BCC,  Danielle Boselli MS,  Ashley E. Strahley MPH,  Sydney-Evelyn L. Gibbs Msgh,  Komal P. Murali PhD, RN, ACNP-BC,  Viraj R. Patel MPH,  Ritesh R. Kotecha MD,  Judith E. Nelson MD, JD, 
  • First Published: 21 March 2025

Hospitalized adults of Dharmic religions (Hinduism, Buddhism, Sikhism, Jainism) with cancer used chaplaincy services less often than those of other religions, with barriers, including unfamiliarity about chaplaincy and concerns about faith-discordancy, resulting in individuals addressing needs independently. The findings suggest a need to develop models of concordant spiritual care.

Disease Site

Hematologic Malignancies

Open Access

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI)

Massimo Breccia MD,  Francesca Palandri MD, PhD,  Maurizio Martelli MD,  Francesco Mendicino MD,  Alessandra Malato MD, PhD,  Giuseppe A. Palumbo MD, PhD,  Silvia Sibilla MD,  Nicola Di Renzo MD,  Elisabetta Abruzzese MD, PhD,  Sergio Siragusa MD,  Monica Crugnola MD,  Carmine Selleri MD,  Fabrizio Pane MD,  Paolo Sportoletti MD,  Bruno Martino MD,  Stefana Impera MD,  Alessandra Ricco MD,  Maria Langella MD,  Paolo Ditonno MD,  Giuseppe Carli MD,  Federico Itri MD,  Anna Marina Liberati MD,  Tiziana Urbano MD,  Agostino Tafuri MD,  Vita Polizzi MD,  Domenico Pastore MD,  Erika Morsia MD,  Giulia Benevolo MD,  Giorgia Micucci MD,  Gabriella Farina MD,  Massimiliano Bonifacio MD,  Elena Maria Elli MD,  Angelo Gardellini MD,  Valerio De Stefano MD,  Giovanni Caocci MD,  Antonietta Pia Falcone MD,  Daniele Vallisa MD,  Marco Brociner MD,  Mario Tiribelli MD,  Gianni Binotto MD,  Barbara Pocali MD,  Francesco Cavazzini MD,  Simona Tomassetti MD,  Francesca Lunghi MD,  Mauro Di Ianni MD,  Alessandro Allegra MD,  Barbara Anaclerio MD,  Serena Mazzotta MD,  Nicola Orofino MD,  Filippo Gherlinzoni MD,  Chiara Castiglioni PharmD,  Marina Landoni PharmD,  Diletta Valsecchi PharmD,  Michela Magnoli MSc,  Paola Guglielmelli MD, PhD,  Francesco Passamonti MD, 
  • First Published: 20 March 2025

The study investigated ruxolitinib dosing patterns and correlations with clinical outcomes in patients with myelofibrosis from the ROMEI study. Timely and optimal ruxolitinib treatment demonstrated maximum patient benefits such as spleen size reduction, symptom relief, and improved overall survival, with manageable safety.

REVIEW ARTICLE

Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges

Jayastu Senapati MD, DM,  Tapan M. Kadia MD,  Naval G. Daver MD,  Courtney D. DiNardo MD,  Gautam Borthakur MD,  Farhad Ravandi MD,  Hagop M. Kantarjian MD, 
  • First Published: 19 March 2025

Treatment options and outcomes in acute myeloid leukemia (AML) are steadily improving with genomically inspired combination approaches and optimization of low-intensity but efficacious therapy. Subgroups of AML such as AML with TP53 aberrations, AML with MECOM gene rearrangement, and relapsed or refractory AML remain challenging, with poor outcomes.

ORIGINAL ARTICLE

Disease Site

Genitourinary Disease

Open Access

Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer

Wataru Fukuokaya MD,  Keiichiro Mori MD, PhD,  Takafumi Yanagisawa MD, PhD,  Fumihiko Urabe MD, PhD,  Pawel Rajwa MD, PhD,  Alberto Briganti MD, PhD,  Shahrokh F. Shariat MD, PhD,  Nobuaki Matsubara MD,  Takahiro Kimura MD, PhD,  Akihiro Hirakawa PhD, 
  • First Published: 19 March 2025

In this post-hoc analysis of a phase 3 randomized controlled trial comparing apalutamide versus placebo in metastatic castration-sensitive prostate cancer, patients with two or less bone metastases had a reduced benefit from apalutamide treatment. Visceral metastasis was not associated with apalutamide benefit.

Discipline

Epidemiology

Lifetime body weight patterns, weight loss, and renal cell carcinoma subtypes

Zhengyi Deng PhD, MBBS,  Chiyuan Amy Zhang MPH,  Justin X. Moore PhD, MPH,  Saira Khan PhD, MPH,  Rebecca E. Graff ScD,  Ken Batai PhD,  Melissa L. Bondy PhD,  Benjamin I. Chung MD,  Marvin E. Langston PhD, MPH, 
  • First Published: 24 March 2025

Lifetime exposure to excess body weight and adult weight gain were associated with increased risks of overall RCC, particularly clear cell RCC. Weight loss across lifetime, however, was associated with a decreased risk of overall RCC.

COMMENTARY

Open Access

Human papillomavirus-related cancers and human papillomavirus vaccination among Arab Americans: A call to unveil disparities and bridge the research gaps

Nada Al-Antary MD,  Nemer Assi BS,  Mrudula Nair BDS, MPH,  Milkie Vu PhD, MA,  Reem F. Siddiqui BSci,  Farzan Siddiqui MD, PhD,  Eric Adjei Boakye PhD, 
  • First Published: 25 March 2025

Arab Americans, a diverse and rapidly growing demographic in the United States, face unique barriers to human papillomavirus (HPV) vaccination and cancer prevention, but there is a notable lack of research on HPV-associated cancer incidence and vaccination rates in this community. Collaborative efforts among health care providers, public health agencies, researchers, and religious community organizations are essential to improve HPV vaccination uptake and reduce cancer disparities within this underserved population by including Middle Eastern and North African as a distinct category in national health surveys, conducting comprehensive epidemiological research, and developing culturally tailored interventions.

ORIGINAL ARTICLE

Disease Site

Hematologic Malignancies

Open Access

INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia

Cristina Papayannidis MD, PhD,  Elisabetta Petracci PhD,  Patrizia Zappasodi MD,  Nicola Fracchiolla MD,  Fabio Ciceri MD,  Chiara Sartor MD, PhD,  Elisa Roncoroni MD,  Francesco Di Raimondo MD,  Daniele Mattei MD,  Maria Benedetta Giannini MD,  Francesco Lanza MD,  Michele Gottardi MD, PhD,  Maria Ilaria Del Principe MD,  Erika Borlenghi MD,  Monica Fumagalli MD,  Daniele Vallisa MD,  Simona Sica MD,  Nicola Di Renzo MD,  Francesco Fabbiano MD,  Elisabetta Todisco MD, PhD,  Paolo de Fabritiis MD,  Mario Luppi MD,  Francesco Passamonti MD,  Paolo Corradini MD,  Fara Petruzziello MD,  Fabrizio Pane MD,  Felicetto Ferrara MD,  Greta Mambelli BSc,  Roberta Volpi BSc,  Federica Frabetti BSc,  Chiara Zingaretti PhD,  Giovanni Marconi MD,  Giovanni Martinelli MD, 
  • First Published: 22 March 2025

This multicenter real-world study confirms that inotuzumab ozogamicin (IO) effectively induces remission and facilitates allogeneic hematopoietic stem cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia by achieving a 74% response rate with manageable toxicity. These findings underscore IO’s role in routine clinical practice for heavily pretreated patients, which offers a viable bridge to curative hematopoietic stem cell transplantation.